IDEAYA Biosciences, Inc. Common Stock
IDYA
IDYA: IDEAYA Biosciences Inc an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations.
moreShow IDYA Financials
Recent trades of IDYA by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by IDYA's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Dihydrothieno[3,2-b]pyridine compounds Feb. 21, 2023
-
Patent Title: Substituted imidazo[1,5-a]pyrazines and [1,2,4]triazolo[4,3-a]pyrazines for the modulation of ahr Dec. 20, 2022
-
Patent Title: Ahr modulators Aug. 09, 2022
-
Patent Title: 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors Sep. 28, 2021
-
Patent Title: 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors Aug. 10, 2021
-
Patent Title: 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors Jun. 29, 2021
-
Patent Title: Ahr modulators Oct. 27, 2020
Federal grants, loans, and purchases
Followers on IDYA's company Twitter account
Number of mentions of IDYA in WallStreetBets Daily Discussion
Recent insights relating to IDYA
Recent picks made for IDYA stock on CNBC
ETFs with the largest estimated holdings in IDYA
Flights by private jets registered to IDYA